Aims

The aim of this study was to describe, analyze, and compare the survival, functional outcome, and complications of minimally invasive (MI) and non-invasive (NI) lengthening total femoral prostheses.

The August 2013 Children’s orthopaedics Roundup³⁶⁰ looks at: a multilevel approach to equinus gait; whether screening leads to needless intervention; salvage of subcapital slipped epiphysis; growing prostheses for children’s oncology; flexible nailing revisited; ultrasound and the pink pulseless hand; and slipping forearm fractures.

In skeletally immature patients, resection of bone tumours and reconstruction of the lower limb often results in leg-length discrepancy. The Stanmore non-invasive extendible endoprosthesis, which uses electromagnetic induction, allows post-operative lengthening without anaesthesia. Between 2002 and 2009, 55 children with a mean age of 11.4 years (5 to 16) underwent reconstruction with this prosthesis; ten patients (18.2%) died of disseminated disease and one child underwent amputation due to infection. We reviewed 44 patients after a mean follow-up of 41.2 months (22 to 104). The mean Musculoskeletal Tumor Society score was 24.7 (8 to 30) and the Toronto Extremity Salvage score was 92.3% (55.2% to 99.0%). There was no local recurrence of tumour. Complications developed in 16 patients (29.1%) and ten (18.2%) underwent revision.

The mean length gained per patient was 38.6 mm (3.5 to 161.5), requiring a mean of 11.3 extensions (1 to 40), and ten component exchanges were performed in nine patients (16.4%) after attaining the maximum lengthening capacity of the implant. There were 11 patients (20%) who were skeletally mature at follow-up, ten of whom had equal leg lengths and nine had a full range of movement of the hip and knee.

This is the largest reported series using non-invasive extendible endoprostheses after excision of primary bone tumours in skeletally immature patients. The technique produces a good functional outcome, with prevention of limb-length discrepancy at skeletal maturity.

Growing prostheses have been utilised in the United Kingdom since the late 1970s. Various mechanisms have been tried, but to date all have required some form of surgical intervention. This has led to multiple hospital admissions and a large amount of resources, both in theatre time and rehabilitation. Over the last ten years the Department of Bio-Medical Engineering at University College, London, together with the Royal National Orthopaedic Hospital, Stanmore, have developed a prosthesis which does not require surgical intervention to elongate. The total cost of the development has been something in the order of £350,000.00. The design features are the power worm screw mechanism where one turn equals 1 mm of elongation, but attached to this mechanism is an epicyclic gearbox, which has been reduced in size so that it can fit in to the body of the prosthesis. The speed reduction achieved by the gear box is 13061 to 1. The mechanism is capable of withstanding an axial load of 1,350 newtons. When an external magnetic field is applied an external coil speed of 3,000 revs per minute leads to a lengthening of 0.23 mm per minute. To date the prosthesis has been inserted in three patients ages 11, 12 and 13. All were suffering from osteosarcoma of the distal femur and had previously received neo-adjuvant chemotherapy. Early elongation had been achieved in all patients without any major discomfort and without the need for either analgesia or inpatient admission. There had been no loss of range of movement in the early post-lengthening period. This new prosthesis represents a significant advance in the management of skeletal sarcomas in children